Talk:Semax: Difference between revisions

>RazorStorm
Fixed a typo of 1.2g to 1.2mg
>Blackhole
removed for some reason doubling approval notice, and updated reflist
Line 1: Line 1:
{{headerpanel|{{approval}}}}
{{SubstanceBox/Semax}}
{{SubstanceBox/Semax}}
'''Semax''' (natively labeled '''Семакс''') is a Russian pharmaceutical [[Peptide|neuropeptide]] developed in the 1980s and approved for clinical use in 1996 after a 14-year-long testing period<ref>http://www.semaxint.com/history.htm</ref>. While commonly prescribed in Russia, Ukraine, and other [https://en.wikipedia.org/wiki/Commonwealth_of_Independent_States CIS] nations for a wide range of conditions including stroke/ischemic brain injury, Alzheimer's, depression, generalized anxiety, peptic ulcer disease, and weakened immune system, it has gained limited recognition elsewhere as a [[nootropic]] due to its mildly [[Stimulants|stimulating]] and [[Anxiety suppression|anxiolytic]] effects, neuroprotective properties, and limited side effect profile.  
'''Semax''' (natively labeled '''Семакс''') is a Russian pharmaceutical [[Peptide|neuropeptide]] developed in the 1980s and approved for clinical use in 1996 after a 14-year-long testing period<ref>http://www.semaxint.com/history.htm</ref>. While commonly prescribed in Russia, Ukraine, and other [https://en.wikipedia.org/wiki/Commonwealth_of_Independent_States CIS] nations for a wide range of conditions including stroke/ischemic brain injury, Alzheimer's, depression, generalized anxiety, peptic ulcer disease, and weakened immune system, it has gained limited recognition elsewhere as a [[nootropic]] due to its mildly [[Stimulants|stimulating]] and [[Anxiety suppression|anxiolytic]] effects, neuroprotective properties, and limited side effect profile.  


Line 85: Line 85:


==References==
==References==
 
{{reflist|2}}
<references />
Return to "Semax" page.